{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:38:05Z","timestamp":1780609085213,"version":"3.54.1"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We measured hepatitis C virus (HCV) adherence via electronic blister packs for 145 people who inject drugs treated on-site in a methadone program. The overall sustained virologic response (SVR) rate was 96% (95% CI, 91%\u201398%), and overall daily adherence was 78% (95% CI, 76%\u201381%). Participants who achieved at least 50% adherence had an overall SVR rate of 99%, with each 5% adherence interval &amp;gt;50% achieving at least 90% adherence. Suboptimal adherence may still lead to cure in the direct-acting antiviral era.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa377","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T06:47:07Z","timestamp":1598424427000},"source":"Crossref","is-referenced-by-count":34,"title":["Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-2245","authenticated-orcid":false,"given":"Brianna L","family":"Norton","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Agyemang","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonseong","family":"Heo","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Clemson University, Clemson, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene-","family":"Pericot-Valverde","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of South Carolina School of Medicine \u2013 Greenville, Greenville, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H","family":"Litwin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of South Carolina School of Medicine \u2013 Greenville, Greenville, South Carolina, USA"},{"name":"Clemson University School of Health Research, Clemson, South Carolina, USA"},{"name":"Prisma Health, Greenville, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"2020102711005604700_CIT0001","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2020102711005604700_CIT0002","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"J Community Health"},{"key":"2020102711005604700_CIT0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1365-2893.2009.01250.x","article-title":"Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals","volume":"17","author":"Treloar","year":"2010","journal-title":"J Viral Hepat"},{"key":"2020102711005604700_CIT0004","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/08897077.2018.1485128","article-title":"Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada","volume":"39","author":"Young","year":"2018","journal-title":"Subst Abus"},{"key":"2020102711005604700_CIT0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020102711005604700_CIT0006","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","volume":"70","author":"Graf","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020102711005604700_CIT0007","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial","volume":"170","author":"Akiyama","year":"2019","journal-title":"Ann Intern Med"},{"key":"2020102711005604700_CIT0008","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"2020102711005604700_CIT0009","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa377\/33683287\/ofaa377.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/10\/ofaa377\/34043517\/ofaa377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/10\/ofaa377\/34043517\/ofaa377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T15:05:24Z","timestamp":1603811124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa377\/5897253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa377","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,8,26]]},"article-number":"ofaa377"}}